Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 870389, 8 pages
http://dx.doi.org/10.1155/2015/870389
Research Article

Virtual Screening of Acetylcholinesterase Inhibitors Using the Lipinski’s Rule of Five and ZINC Databank

1Departamento de Bioquímica e Biologia Molecular, Programa de Pós-Graduação em Ciências Biológicas: Bioquímica Toxicológica, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, 97105-900 Santa Maria, RS, Brazil
2Grupo de Estudos em Bioquímica, Farmacologia e Toxicologia Molecular, Unidade Acadêmica de Serra Talhada, Universidade Federal Rural de Pernambuco, 56900-000 Serra Talhada, PE, Brazil

Received 23 May 2014; Revised 16 July 2014; Accepted 17 July 2014

Academic Editor: Miroslav Pohanka

Copyright © 2015 Pablo Andrei Nogara et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Harman, “A hypothesis on the pathogenesis of Alzheimer's disease,” Annals of the New York Academy of Sciences, vol. 786, pp. 152–168, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. D. J. Selkoe, “Cell biology of protein misfolding: the examples of Alzheimer's and Parkinson's diseases,” Nature Cell Biology, vol. 6, no. 11, pp. 1054–1061, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. L. J. Launer, L. Fratiglioni, K. Andersen et al., “Regional differences in the incidence of Dementia in Europe-EURODEM collaborative analysis,” in Alzheimer’s Disease and Related Disorders: Etiology, Pathogenesis and Therapeutics, K. Iqbal, D. F. Swaab, B. Winblad, and H. M. Wisniewski, Eds., pp. 9–15, John Wiley & Sons, New York, NY, USA, 1999. View at Google Scholar
  4. J. L. Cummings and C. Back, “The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease,” The American Journal of Geriatric Psychiatry, vol. 6, no. 2, pp. S64–S78, 1998. View at Publisher · View at Google Scholar · View at Scopus
  5. P. Kása, Z. Rakonczay, and K. Gulya, “The cholinergic system in alzheimer's disease,” Progress in Neurobiology, vol. 52, no. 6, pp. 511–535, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Silman and J. L. Sussman, “Acetylcholinesterase: “classical” and “non-classical” functions and pharmacology,” Current Opinion in Pharmacology, vol. 5, no. 3, pp. 293–302, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Enz, R. Amstutz, H. Boddeke, G. Gmelin, and J. Malanowski, “Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease,” Progress in Brain Research, vol. 98, pp. 431–438, 1993. View at Publisher · View at Google Scholar · View at Scopus
  8. M. Jalaie and V. Shanmugasundaram, “Virtual screening: are we there yet?” Mini-Reviews in Medicinal Chemistry, vol. 6, no. 10, pp. 1159–1167, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney, “Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings,” Advanced Drug Delivery Reviews, vol. 23, no. 1–3, pp. 3–25, 1997. View at Publisher · View at Google Scholar · View at Scopus
  10. D. B. Kitchen, H. Decornez, J. R. Furr, and J. Bajorath, “Docking and scoring in virtual screening for drug discovery: methods and applications,” Nature Reviews Drug Discovery, vol. 3, no. 11, pp. 935–949, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. J. J. Irwin and B. K. Shoichet, “ZINC—a free database of commercially available compounds for virtual screening,” Journal of Chemical Information and Modeling, vol. 45, no. 1, pp. 177–182, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. D. F. Veber, S. R. Johnson, H.-Y. Cheng, B. R. Smith, K. W. Ward, and K. D. Kopple, “Molecular properties that influence the oral bioavailability of drug candidates,” Journal of Medicinal Chemistry, vol. 45, no. 12, pp. 2615–2623, 2002. View at Publisher · View at Google Scholar · View at Scopus
  13. O. Trott and A. J. Olson, “Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading,” Journal of Computational Chemistry, vol. 31, no. 2, pp. 455–461, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. B. D. Bursulaya, M. Totrov, R. Abagyan, and C. L. Brooks III, “Comparative study of several algorithms for flexible ligand docking,” Journal of Computer-Aided Molecular Design, vol. 17, no. 11, pp. 755–763, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. G. L. Ellman, K. D. Courtney, V. Andres Jr., and R. M. Featherstone, “A new and rapid colorimetric determination of acetylcholinesterase activity,” Biochemical Pharmacology, vol. 7, no. 2, pp. 88–95, 1961. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Worek, P. Eyer, D. Kiderlen, H. Thiermann, and L. Szinicz, “Effect of human plasma on the reactivation of sarin-inhibited human erythrocyte acetylcholinesterase,” Archives of Toxicology, vol. 74, no. 1, pp. 21–26, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. D. B. Rosemberg, R. F. da Rocha, E. P. Rico et al., “Taurine prevents enhancement of acetylcholinesterase activity induced by acute ethanol exposure and decreases the level of markers of oxidative stress in zebrafish brain,” Neuroscience, vol. 171, no. 3, pp. 683–692, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. M. J. Castro, V. Richmond, C. Romero et al., “Preparation anticholinesterase activity and molecular docking of new lupane derivatives,” Bioorganic & Medicinal Chemistry, vol. 22, pp. 3341–3350, 2014. View at Google Scholar
  19. P. Camps, X. Formosa, C. Galdeano et al., “Tacrine-based dual binding site acetylcholinesterase inhibitors as potential disease-modifying anti-Alzheimer drug candidates,” Chemico-Biological Interactions, vol. 187, no. 1–3, pp. 411–415, 2010. View at Publisher · View at Google Scholar · View at Scopus